Alyeska Investment Group
PSTX

Alyeska Investment Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Alyeska Investment Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$549K – 851
2020
Q4 		$549K Buy
+50,000
New +$527K 0.01% 446

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's PSTX Position: Q1 2021 in Review

Alyeska Investment Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2021, closing a stake of 50,000 shares — an estimated $549K sold.

Alyeska Investment Group first reported a position in PSTX in Q4 2020 and held it in 1 quarter. The position peaked at $549K in Q4 2020. 62 funds tracked by Wall St. Rank hold PSTX as of Q1 2021.

  • Alyeska Investment Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $549K.
  • Alyeska Investment Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Alyeska Investment Group's Poseida Therapeutics, Inc. Common Stock position peaked at $549K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.